Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SORD | Q00796 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21516286 | 0.90 | CXCR4 (0.47) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516076 | 0.90 | CXCR4 (0.59) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516071 | 0.89 | CXCR4 (0.46) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516609 | 0.89 | CXCR4 (0.46) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516290 | 0.89 | CXCR4 (0.48) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516041 | 0.88 | CXCR4 (0.45) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516742 | 0.86 | CXCR4 (0.44) | CXCR4ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL21516291 | 0.86 | CXCR4 (0.44) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516036 | 0.85 | CXCR4 (0.47) | CXCR4ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL21516283 | 0.83 | CXCR4 (0.41) | CXCR4ALDH1A1LMNAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332470-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20190322671-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322671-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | CXCR4 1/4885ALDH1A1 1512/4885LMNA 4057/4885 |
| US-11332470-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | CXCR4 1/4885ALDH1A1 1512/4885LMNA 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.